Cervarix FDA Approval History
FDA Approved: Yes (Discontinued) (First approved October 16, 2009)
Brand name: Cervarix
Generic name: human papillomavirus bivalent (types 16 and 18) vaccine, recombinant
Dosage form: Injection
Treatment for: Human Papillomavirus Prophylaxis
Marketing Status: Discontinued
Cervarix (human papillomavirus bivalent (types 16 and 18) is a is a preventative cervical cancer vaccine for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 in girls and young women (aged 10-25).
Development Timeline for Cervarix
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.